Mark E. Bunnage

EVP, Chief Scientific Officer, Vertex Pharmaceuticals

Bought, 12 months

$0.0M

Sold, 12 months

$3.0M

Companies

Latest trade

May 15, 2026

Companies

Vertex PharmaceuticalsEVP, Chief Scientific Officer −$3.0M

Trades

VRTX Sold 33 shares at $453.45 · planned $0.0M May 15

VRTX Sold 620 shares at $486.35 · planned $0.3M Feb 25

VRTX Sold 1,182 shares at $473.68 · planned $0.6M Feb 18

VRTX Sold 2,437 shares at $489.46 · planned $1.2M Feb 17

VRTX Sold 2,021 shares at $460.43 · planned $0.9M Feb 11

Open-market trades from SEC Form 4 only: no grants, option exercises or gifts. People are matched by the name on their filings, so two people with the same name share this page. For information only — not investment advice.